Author: Angeline Leishman|| Date Published: December 30, 2021
Merck’s life science business has been awarded a three-year, $136.7 million contract to stand up a factory for a critical material needed to manufacture rapid COVID-19 point-of-care tests.
MilliporeSigma said Thursday it will use the funds to establish a lateral flow membrane production facility in Sheboygan, Wisconsin, to support domestic production and supply efforts for the government’s pandemic preparedness initiative.
The business supplies its Hi-Flow Plus nitrocellulose membrane to manufacturers of medical test kits intended to diagnose infectious diseases such as COVID-19, malaria and HIV.
Space Force awards Northrop $398M SATCOM satellite prototype contract The program aims to strengthen communications in contested environments The award…
Nine companies win spots on Navy unmanned systems contract Work covers design, testing, deployment and sustainment support Autonomous maritime platforms…
Anthropic reportedly explores massive new funding round Anthropic deepens focus on AI-driven cyber defense and national security Its growth highlights…